We are thrilled to share that Rarity Bioscience together with Karolinska Institutet and Uppsala University are nominated to the ESCCA Best Abstract Award, for the abstract “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay.”. A spart of that we have been awarded a plenary session presentation. Come and listen and talk to us!
The abstract tells how the superRCA assays can detect single point mutations as low as 1 in 100,000 with a standard flow cytometer readout, and with this ultra-high sensitivity, it’s even possible to monitoring the status of AML patient with blood samples with equal utility comparing to the bone marrow samples.
From the abstract:
“Rare tumor-specific mutations in patient samples serve as excellent markers to monitor the course of malignant disease and responses to therapy in clinical routine, and improved assay techniques are needed for broad adoption. We describe herein – superRCA assays – which provides for rapid and highly specific detection of DNA sequence variants present at very low frequencies in DNA samples.”
We will be presenting the abstract at the ESCCA 2023 Conference
Thursday 28th of September at 14.00 in room PLE04-01
You find us just outside the presentation hall before the presentation, and after the presentation we will be available for a coffee and a chat outside the presenting room, ready to answer any questions you might have.
We look forward seeing you there!
Linus, Alexander and Lei
